Filtered By:
Source: Health Economics Review
Condition: Bleeding
Management: Economics
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Estimation of the cost-effectiveness of apixaban versus vitamin K antagonists in the management of atrial fibrillation in Argentina
Abstract
Apixaban, a novel oral anticoagulant which has been approved for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation, reduces both ischemic and haemorrhagic stroke and produces fewer bleedings than vitamin K antagonist warfarin. These clinical results lead to a decrease in health care resource utilization and, therefore, have a positive impact on health economics of atrial fibrillation. The cost-effectiveness of apixaban has been assessed in a variety of clinical settings and countries. However, data from emergent markets, as is the case of Argentina, are still scarce.
...
Source: Health Economics Review - June 26, 2015 Category: Global & Universal Source Type: research
